Drug Trial Radar · NCT02134977
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: "QOL Survey in Premenopausal Breast Cancer Patients"
Last checked: Nov 19, 2026Latest source record: Oct 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,816
Actual
Start
Sep 2011
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- May 9, 2014
Design
- Study type
- Observational
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this survey is to examine the effect on quality of life (QOL) improvement and convenience of switching to leuprorelin acetate 3 months depot 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) from a 4-week adjuvant therapy with a luteinizing hormone-releasing hormone analog (LH-RHa) 1 month depot over 48 weeks in premenopausal breast cancer participants in daily medical practice. Influence of condition of estrogen receptor expression on the efficacy and safety of leuprorelin acetate SR 11.25 mg injection kit was also evaluated.
Conditions
- Breast Cancer
Interventions
Leuprorelin AcetateDrug
Leuprorelin Acetate SR 11.25 mg Injection Kit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD) Total and Subscale Score at BaselineTime frame: Baseline
- QOL-ACD Total and Subscale Score at Week 12Time frame: Week 12
- QOL-ACD Total and Subscale Score at Week 48Time frame: Week 48
- QOL-ACD Breast (QOL-ACD-B) Score at BaselineTime frame: Baseline
- Score of QOL-ACD-B at Week 12Time frame: Week 12
- Score of QOL-ACD-B at Week 48Time frame: Week 48
- Score of QOL-ACD-B Items 19, 20 and 21 at BaselineTime frame: Baseline
- Score of QOL-ACD-B Items 19, 20 and 21 at Week 12Time frame: Week 12
- Score of QOL-ACD-B Items 19, 20 and 21 at Week 48Time frame: Week 48
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.